- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01188031
A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions
A Relative Bioavailability Study of 2 mg Alprazolam Oral Disintegrating Tablets Under Fasting Conditions
Study Overview
Status
Conditions
Detailed Description
Study Type: Interventional Study Design: This was a single-center, randomized, two-way crossover study conducted under fasting conditions Official Title: A Relative Bioavailability Study of 2 mg Alprazolam Oral Disintegrating Tablets under Fasting Conditions
Further study details as provided by Actavis Elizabeth LLC:
Primary Outcome Measures:
Rate and Extend of Absorption
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Dakota
-
Fargo, North Dakota, United States, 58102
- PRACS Institute, Ltd.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects who met the following criteria were included in the study.
- Volunteers who were informed of the nature of the study and who read, reviewed, and signed the informed consent prior to Period I dosing.
- Volunteers who completed the screening process within 28 days prior to Period I dosing.
- Volunteers who were healthy adult men and women 18 years of age or older at the time of dosing.
- Volunteers who had a body mass index (BMI) between 18-32 kg/nr', inclusive, and weighed at least 110 lbs.
- Volunteers who were healthy as documented by the medical history, physical examination (including but may not be limited to an evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous systems), vital sign assessments, 12-lead electrocardiogram (ECG), clinical laboratory assessments, and by general observations. Any abnormalities/deviations form the normal range that were considered clinically relevant by the study physician and investigator were evaluated for individual cases, documented in study files, and agreed upon by both the study physician and investigator prior to enrolling the volunteer in this study and for continued enrollment.
- Female volunteers ofpostmenopausal (no menses) status for at least 1 year and has a serum FSH level 2: 30 mlU/mL or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy.)
Exclusion Criteria:
Subjects who met any ofthe following criteria were excluded from the study.
- Volunteers who reported receiving any investigational drug within 28 days prior to Period I dosing.
- Volunteers who reported any presence or history of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease as determined by the clinical investigator(s).
- Volunteers whose clinical laboratory test values outside the accepted reference range and, when confirmed on re-examination, were deemed clinically significant.
- Volunteers who demonstrated a reactive screen for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody.
- Volunteers who reported a history of allergic response(s) to alprazolam or related drugs.
- Volunteers who reported the use of any systemic prescription medication in the 14 days prior to Period I dosing.
- Volunteers who reported the use of any drug known to induce or inhibit hepatic drug metabolism in the 28 days prior to Period I dosing.
- Volunteers who reported a history ofclinically significant allergies including drug allergies.
- Volunteers who reported a clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the clinical investigators).
- Volunteers who reported a history of drug or alcohol abuse addiction or abuse within the past year.
- Volunteers who demonstrated a positive drug abuse screen for this study prior to Period I dose administration.
- Volunteers who currently used tobacco products.
- Volunteers who reported donating greater than 150 mL ofblood within 28 days prior to Period I dosing. All subjects were advised not to donate blood for four weeks after completing the study.
- Volunteers who donated plasma (e.g. plasmapheresis) within 14 days prior to Period I dosing. All subjects were advised not to donate plasma for four weeks after completing the study
- Volunteers who demonstrated a positive pregnancy screen (females only).
- Volunteers who were currently pregnant or breastfeeding (females only).
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ALPRAZOLAM ORALLY DISINTEGRATING TABLETS
ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, single dose
|
A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under fasting conditions
Other Names:
|
ACTIVE_COMPARATOR: NIRAVAM TM
NIRAVAM TM 2 mg orally disintegrating tablets, single dose
|
B: Active comparator Subjects received Schwarz Pharma Inc. formulated products under fasting conditions
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate and Extend of Absorption
Time Frame: 72hr
|
72hr
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R06-0302
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG
-
Actavis Inc.Completed
-
First Affiliated Hospital of Zhejiang UniversityShenyang Sunshine Pharmaceutical Co., LTD.UnknownImprovement of Pruritus in Hemodialysis PatientsChina
-
PfizerBioshin (Shanghai) Consulting Services Co., LtdCompleted
-
Cara Therapeutics, Inc.RecruitingPruritus | Notalgia ParestheticaUnited States, Poland, Spain, Canada, Germany
-
Eisai Inc.CompletedPurpura, Thrombocytopenic, Idiopathic | Chronic Thrombocytopenia | Acute Idiopathic Thrombocytopenic PurpuraNetherlands
-
University of MichiganTerminated
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Ferring PharmaceuticalsCompletedOveractive BladderUnited States
-
Teva Pharmaceuticals USACompleted